Primary Objective~1.Evaluate in a standardized manner in each subpopulation the humoral immune response to Covid-19 vaccination at 1, 6, 12, 24 months (M) after the last dose of vaccine (1 or 2 dose schedule depending on the vaccines) and standardized assessment of the humoral response 1 month after receipt of the third injection in participants receiving a third injection as recommended~Secondary objectives~Evaluate the cellular immune response to Covid-19 vaccination at Inclusion, 6 and 24 months after the first injection (single-injection scheme) or after the second injection of the vaccine (two or three-injections regimens) in each subpopulation~Compare the humoral immune response at 1, 6, 12, 24 months after the first injection (one-injection scheme) or after the second injection of vaccine (two- or three-injections regimens) of each subpopulation with a control group of subjects without the chronic diseases of interest and from any other diseases or treatment taht may have an influence on the immune response.~Compare the humoral immune response after 3 injections (1 month after the third dose) to that after 2 injections (1 month after the second dose) in participants with received a third injection as current recommendations~In each subpopulation, study the factors associated with the humoral immune response at 1 month and the persistence of the humoral immune response at 6, 12, 24 months as a function of age, stage of disease, treatments, type of vaccine (as well as characteristics specific to the subpopulations studied)~Evaluate and characterize the humoral immune response for participants who received a booster dose with mRNA vaccine acording to recommendations in force~Compare the humoral immune response between different specific subpopulations~Describe the seroconversion for anti-nucleoprotein antibodies~Immuno-virologically characterize vaccine failures (SARS-CoV2 infection) during follow-up~Identify genetic determinants of the immune response based on the underlying pathology and ongoing treatments if applicable (response and resistance to vaccination)~Specifics secondary objectives for participants with the first dose of Astra-Zeneca vaccine and the second dose of Pfizer vaccine~Evaluate the humoral and the cellular immune response to Covid-19 vaccination with this vaccination schedule~Evaluate the clinical reaction (local and generale) after this vaccination schedule
Multicentre national cohort study with prospective data collection and biological specimen collection.~Ancillary study in this cohort : pediatric cohort with participants from 5 to 17 years old.~Enrollment complete for adult cohort. Active recruting for ancillary pediatric cohort.